https://orcid.org/0000-0003-4001-3036
References
- Freidlin, B., and Korn, E. L. (2019), “Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?” Journal of Clinical Oncology, 37, 3455–3459. DOI: 10.1200/JCO.19.01681.
- Huang, B. (2018), “Some Statistical Considerations in the Clinical Development of Cancer Immunotherapies,” Pharmaceutical Statistics, 17, 49–60. DOI: 10.1002/pst.1835.
- Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J. Z., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.-T., and Iacona, R. (2020a), “Alternative Analysis Methods for Time to Event Endpoints Under Nonproportional Hazards: A Comparative Analysis,” Statistics in Biopharmaceutical Research, 12, 187–198. DOI: 10.1080/19466315.2019.1697738.
- Lin, R. S., Lin, J., Roychoudhury, S., Anderson, K. M., Hu, T., Huang, B., Leon, L. F., Liao, J. J. Z., Liu, R., Luo, X., Mukhopadhyay, P., Qin, R., Tatsuoka, K., Wang, X., Wang, Y., Zhu, J., Chen, T.-T., and Iacona, R. (2020b), “Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios,” Statistics in Biopharmaceutical Research, 12, 520–521. DOI: 10.1080/19466315.2020.1825522.
- Luo, X., Sun, Y., and Xu, Z. (2022), “A MCP-Mod Approach to Designing and Analyzing Survival Trials with Potential Non-proportional Hazards,” Pharmaceutical Statistics, 1–15. DOI: 10.1002/pst.2241..
- Magirr, D., and Burman, C.-F. (2021), “The Strong Null Hypothesis and the MaxCombo Test: Comment on “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance from a Cross-Pharma Working Group,” Statistics in Biopharmaceutical Research, 1–2. DOI: 10.1080/19466315.2021.1917451.
- Maurer, W., and Bretz, F. (2013), “Multiple Testing in Group Sequential Trials Using Graphical Approaches,” Statistics in Biopharmaceutical Research, 5, 311–314. DOI: 10.1080/19466315.2013.807748.
- Mukhopadhyay, P., Huang, W., Metcalfe, P., Ohrn, F., Jenner, M., and Stone, A. (2020), “Statistical and Practical Considerations in Designing of Immuno-Oncology Trials,” Journal of Biopharmaceutical Statistics, 30, 1130–1146. DOI: 10.1080/10543406.2020.1815035.
- Roychoudhury, S., Anderson, K. M., Ye, J., and Mukhopadhyay, P. (2021), “Robust Design and Analysis of Clinical Trials with Nonproportional Hazards: A Straw Man Guidance from a Cross-Pharma Working Group,” Statistics in Biopharmaceutical Research, 1–15. DOI: 10.1080/19466315.2021.1874507.
- Shen, Y.-L., Wang, X., Sirisha, M., Mulkey, F., Zhou, J., Gao, X., Zhang, L., Gwise, T., Tang, S., Theoret, M., Pazdur, R., and Sridhara, R. (2022), “Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials,” Statistics in Biopharmaceutical Research, 1–10. DOI: 10.1080/19466315.2021.2008485.